CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits.

Citation data:

IBRO reports, ISSN: 2451-8301, Vol: 2, Page: 47-53

Publication Year:
2017
Usage 8
Abstract Views 8
Captures 13
Readers 13
Mentions 1
News Mentions 1
Social Media 39
Shares, Likes & Comments 39
Citations 2
Citation Indexes 2
PMID:
30135932
DOI:
10.1016/j.ibror.2017.03.001
Author(s):
Vieira, Fernando G; Hatzipetros, Theo; Thompson, Kenneth; Moreno, Andy J; Kidd, Joshua D; Tassinari, Valerie R; Levine, Beth; Perrin, Steven; Gill, Alan
Publisher(s):
Elsevier BV
Tags:
Neuroscience
Most Recent News Mention
article description
A copper chelator known as diacetylbis(N(4)-methylthiosemicarbazonato) copper II (CuATSM), has been reported to be efficacious in multiple transgenic SOD1 models of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder affecting motor neurons. Here we report that we also observed CuATSM efficacy on disease onset and progression in a standardized litter-matched and gender-balanced efficacy study using B6SJL-SOD1G93A/1Gur mice. We also report improved survival trends with CuATSM treatment. In addition, we report a lack of efficacy by unmetallated ATSM in the same model using the same standardized study design. These results add to existing evidence supporting an efficacious role for copper delivery using chaperone molecules in mouse models of ALS.